Soleus Capital Management’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
Other funds holding UTHR
Soleus Capital Management's UTHR Position: Q3 2026 in Review
Soleus Capital Management increased its United Therapeutics (UTHR) stake by 15% in Q3 2026, buying an estimated $17.3M and bringing the position to 259,000 shares worth $140M. The position accounts for 4.99% of the portfolio, ranked #5.
Soleus Capital Management first reported a position in UTHR in Q3 2021 and has held it in 21 quarters since. 846 funds tracked by Wall St. Rank hold UTHR as of Q3 2026.
- Soleus Capital Management held 259,000 shares of United Therapeutics worth $140M as of Q3 2026.
- Soleus Capital Management bought 33,413 United Therapeutics shares in Q3 2026, an estimated $17.3M.
- United Therapeutics made up 4.99% of Soleus Capital Management's portfolio in Q3 2026, its #5 holding.
- Soleus Capital Management first reported a position in United Therapeutics in Q3 2021 and has held it in 21 quarters since.
- 846 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2026.
Based on Soleus Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.